67 results about "Insulin secretion" patented technology

Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I):wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. An insulin secretion-promoting action of the pentadecanoic acid triglyceride at the time of elevated blood glucose level is discovered, and pharmaceuticals and health foods for improving blood glucose level and diabetes are provided using this triglyceride.

The main objective of this invention is to provide a novel manufacturing method capable of efficiently and directly converting or inducing somatic cells into insulin-producing cells. As an example, a method for manufacturing insulin-producing cells is provided, which involves directly differentiating and inducing insulin production from somatic cells. This method includes a step of culturing somatic cells in a serum-free differentiation-induction medium; or a step of culturing somatic cells in a differentiation-induction medium containing 5 μg / mL or more of insulin. According to this invention, insulin-producing cells with high insulin secretion capacity can be efficiently and directly manufactured from somatic cells. The insulin-producing cells obtained by this invention are useful in regenerative medicine and the like.

Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The invention relates to application of insulin and analogues thereof in preparation of medicines for preventing or treating Alzheimer's disease. Researches find that the damage effect of A beta on insulin secretion depends on CX3CR1, the blood plasma insulin level of AD model mice can be recovered by supplementing exogenous insulin, and the A beta has the treatment effects of improving cognitive impairment of AD model mice, improving cerebrovascular lesion, recovering brain glycometabolism function, relieving brain inflammatory response and the like; the invention provides an alternative medicine with definite curative effect, high safety and affordable price for Alzheimer's disease, expands the indications of insulin and analogues thereof, and has wide market prospect and important social significance.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

The compositions and methods for improving or regulating GLP-1 levels, stimulating GLP-1 secretion, ameliorating metabolism including losing weight, managing glucose or insulin tolerance including stimulating insulin secretion, inhibiting glucagon secretion and reducing fasting glucose levels. The compositions comprise β-aminoisobutyric acid, a physiologically acceptable salt, polymer, ester, or 3-hydroxy-3-methylbutanoic acid, a physiologically acceptable salt, polymer, ester, or tributyrin or tributyrin derivative, or mixture thereof.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

To provide a cell device that allows quicker induction of insulin secretion and suppression of insulin secretion from the initiation of operation, and also to provide a method for controlling insulin secretion.SOLUTION: A cell device 1 comprises: a culture vessel 2; a medium 3 and pancreatic β-cells 4 accommodated in the culture vessel 2; a working electrode 5, to which the pancreatic β-cells 4 adhere and which contains PEDOT:PzSS; a counter electrode 6 provided so as to be in contact with the medium 3; and a potential-application section 8 that applies a potential to the pancreatic β-cells 4 by means of the working electrode 5 and the counter electrode 6.SELECTED DRAWING: Figure 3

The invention discloses a stem cell medicine for pancreas islet repair and application, and belongs to the technical field of stem cell biology, and the stem cell medicine for pancreas islet repair is prepared by compounding a carrier, pancreatic progenitor cells and pancreas islet-like cells in proportion. The problems that in the prior art, due to the fact that stem cells are unstable in differentiation efficiency, poor in synergistic effect and poor in biocompatibility, islet injury cannot be repaired, and diabetes cannot be treated are solved. According to the present invention, the dual mechanisms of endogenous beta cell repair and exogenous beta cell supplement are adopted, and the beta cell function recovery and the group structure reconstruction are synchronously achieved through the reasonable ratio, such that the in-vivo blood glucose of the mouse is significantly reduced, the beta cell number and the glucose tolerance dose of the mouse are increased, and the low immunogenicity and the high anti-inflammatory property are simultaneously provided. The compound can be used for treating type I and type II diabetes mellitus, improving the insulin secretion function and relieving local inflammatory response of pancreas by promoting pancreas islet beta cell proliferation, and has application potential in treatment of type I and type II diabetes mellitus and pancreas islet repair.

The application provides a construction method of a cell model for screening hypoglycemic drugs, and belongs to the technical field of biotechnology.The method provided by the application comprises the following steps: cell verification, vector construction and plasmid extraction, cell electroporation, drug screening, stable strain amplification and Q-PCR verification.The application successfully constructs a stable fluorescence reporter model (Min6-ins2>EGFP) based on Min6 cells, and verifies the specificity and sensitivity of the model to insulin secretion promoting drugs through positive drug verification.The model is simple to operate, can be monitored in real time, is suitable for high-throughput screening, can be effectively used for hypoglycemic activity evaluation of complex components such as chemical drugs and traditional Chinese medicines, and provides a reliable tool for early screening of hypoglycemic drugs.

The invention relates to an application of PBX1 as an active component in preparation of type 2 diabetes mellitus drugs or medical instruments, so as to relieve symptoms of diabetes mellitus, promote repair and regeneration of damaged pancreas islets and improve functions of insulin. The symptoms comprise water intake, food intake and fasting blood glucose; the method for promoting the repair and regeneration of the damaged pancreas islet comprises the steps of inhibiting the apoptosis of pancreas islet beta cells of diabetic mice, promoting the proliferation of the beta cells and recovering the tissue structure of the damaged pancreas islet; the function of improving the pancreas islet comprises the steps of stimulating secretion of insulin, improving the level of an insulin receptor, promoting absorption of an organism to glucose and reducing serum hyperglycemia and HbA1c concentration of diabetic mice, so that the effect of treating both symptoms and root causes of diabetes is achieved.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and / or reversing, returning blood glucose concentration to a normal level in a diabetic.

To provide polypeptide-containing pharmaceutical compositions.SOLUTION: The invention relates to a pharmaceutical composition comprising a polypeptide, more specifically, a pharmaceutical composition for preventing or treating obesity, diabetes or non-alcoholic fatty liver disease. Th pharmaceutical composition is safe without any side effects such as nausea or vomiting with effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. The invention relates to a polypeptide-containing pharmaceutical composition, medical use of the polypeptide-containing pharmaceutical composition, for example, use in treatment or prevention of obesity, diabetes or non-alcoholic fatty liver disease.SELECTED DRAWING: None

Chimeric polypeptides that have the ability to stimulate insulin secretion and that have natriuretic actions are provided herein. For example, provided herein are chimeric polypeptides containing a GLP-1-like region that can stimulate insulin secretion, and a NP-like region having natriuretic activity. Methods for using the chimeric polypeptides described herein to treat mammals having, for example, diabetes mellitus, cardiovascular disease, metabolic syndrome, nonalcoholic fatty liver disease, and / or obesity also are provided herein.

The application discloses a pre-meal nerve electric stimulation control method, device and system. The method comprises the following steps: detecting whether a pre-meal intervention condition is met; when the pre-meal intervention condition is met, generating a biphasic pulse electric stimulation by calling preset output parameters, wherein the preset output parameters comprise a constant stimulation frequency, a constant stimulation pulse width and a stimulation current; and controlling an electrode sheet to output the biphasic pulse electric stimulation to a target vagus nerve site. By outputting the biphasic pulse electric stimulation to the target vagus nerve site when the pre-meal intervention condition is met, the target vagus nerve can be quickly activated before a meal, the body is prepared for adjusting insulin secretion in advance, the postprandial blood glucose peak value can be more effectively flattened, the intervention effect is improved, and thus standard weight management is realized.

The invention discloses an application of WBSCR16 protein as a target spot in preparation of a medicine for treating diabetes, and provides an application in research and development of related medicines. By constructing a mouse model of Wbscr16 with pancreatic beta cells specifically knocked out, the action mechanism of WBSCR16 in diabetes mellitus attack is deeply researched, and it is found that WBSCR16 participates in regulating the mitochondrial function of the pancreatic beta cells, and then insulin secretion is affected. On the basis, the invention provides a reagent for regulating the expression of the WBSCR16 protein for treating diabetes mellitus. Meanwhile, a construction method of the Wbscr16 pancreatic beta cell specific knockout mouse model is described in detail, and an important tool is provided for related research. Meanwhile, candidate drugs capable of acting on a WBSCR16 target spot are screened out through drug prediction, and a new strategy and a potential intervention direction are provided for treatment of diabetes mellitus.

The invention discloses an application of bifidobacterium animalis subsp. Lactis SS9 in preparation of a product for preventing and treating stress obesity. The bifidobacterium animalis subsp. Lactis SS9 obtained by screening can remarkably relieve obesity induced by combination of chronic pressure and high-fat diet, and the obesity is represented by slowing down weight increase, reducing appetite, improving blood fat, up-regulating GLP-1 and insulin secretion and effectively relieving anxiety-like and depression-like behaviors. Researches find that the strain can regulate the hypothalamic-pituitary-adrenal axis activation level, improve secretion imbalance of hormones such as CRH, ACTH and CORT, restore expression of appetite regulation factors such as NPY / AgRP / POMC of hypothalamic and relieve emotional eating behaviors. In addition, the strain can also reduce the systemic inflammation level, recover the diversity of intestinal flora and improve the proportion of beneficial bacteria. The invention provides the probiotics with multiple effects of regulating emotion, controlling body weight and improving metabolic disorder, and a new strategy is provided for preventing and treating stress-related obesity.

The invention discloses a hyriopsis cumingii hypoglycemic polypeptide and application thereof. The amino acid sequence of the hyriopsis cumingii hypoglycemic polypeptide is as shown in SEQ ID NO.01. The IC50 value of the hyriopsis cumingii hypoglycemic polypeptide to alpha-glucosidase is 0.293 mmol / L, the IC50 value of the hyriopsis cumingii hypoglycemic polypeptide to dipeptidyl peptidase-IV is 34.78 mu mol / L, postprandial blood sugar rise can be effectively inhibited, insulin secretion is promoted, and the hyriopsis cumingii hypoglycemic polypeptide is suitable for adjuvant therapy and blood sugar management of type II diabetes patients.

The invention discloses a fusion protein for regulating and controlling functions of pancreatic beta cells based on an optogenetics technology and application of the fusion protein, and relates to the technical field of biology. The fusion protein Opto LOVTRAP disclosed by the invention has very high temporal-spatial resolution, and rapid and accurate control on a single cell can be realized by adjusting blue light; opto LOVTRAP has reversibility, can effectively inhibit a pancreatic beta cell Ca < 2 + > channel under a dark condition, and can quickly stop playing a role after being stimulated by blue light, so that the purpose of reversibly and accurately regulating insulin secretion is achieved. Opto LOVTRAP is targeted to regulate the concentration of Ca < 2 + > in cells, and is a final triggering factor for release of pancreas islet vesicles, so that the opto LOVTRAP is not influenced by the KATP function, and the purpose of breaking through the bottleneck of a traditional clinical treatment mode is achieved.

The invention belongs to the field of biological pharmacy, and relates to a dipeptidyl peptidase IV inhibitory oligopeptide and application thereof. Specifically, the DPP-IV inhibitory peptide is designed by computer-aided design. The polypeptide with DPP-IV inhibitory activity is screened out through virtual amino acid mutation, online database prediction, molecular docking and other methods. The invention proves that the LAFPGSW polypeptide can obviously improve the physiological indexes of diabetic mice, has no toxic or side effect, and can relieve the change of mouse liver weight and mouse body weight caused by diabetes, so that the mouse liver weight and the mouse body weight are recovered to a normal level; according to the present invention, the compound can significantly reduce the levels of AST, ALT, TC and TG in serum, and relieve LDL-C and HDL-C abnormality, such that the compound has effects of blood sugar lowering, lipid lowering, insulin secretion promoting, insulin resistance improving and the like, and can be used for prevention and treatment of diabetes and diabetic complications.

The present invention relates to a pharmaceutical composition and a health functional food composition for regulating and improving blood glucose, each comprising, as an active ingredient, a fermented culture supernatant of a Bacillus velezensis KMU01 strain, a concentrate thereof, a dried product thereof, a fermentation metabolite thereof, or a mixture thereof, and having the effects of regulating insulin secretion in serum and lowering fasting blood glucose.

The invention discloses a hydrogel modified glimepiride nano-drug as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) dissolving an ERLPO polymer and glimepiride into acetone at 40 DEG C to form a uniform organic solvent; (2) stirring the GLM-ERLPO and BP, and centrifuging after the stirring is finished; (3) adding an ENTPD3 antibody, and stirring for reaction; and (4) carrying out hydrogel wrapping to generate a final product GLM-ERLPO-BP-ENTPD3 (at) GEL. The nano-drug provided by the invention can be applied to treating type 2 diabetes and improving the oral nano-drug applied to glimepiride, is high in drug loading rate and good in biocompatibility, can effectively reduce the blood sugar of a mouse with the type 2 diabetes and increase the secretion of insulin from the source, improves the bioavailability of the glimepiride in a body, and can be used for preparing the glimepiride oral nano-drug for treating the type 2 diabetes and the glimepiride oral nano-drug for improving the application of the glimepiride. A new research idea is provided for the application of the glimepiride.

The invention provides application of a lobular formosan lattuce herb extract with a function of regulating insulin secretion of pancreatic beta cells in preparation of a hypoglycemic drug, and relates to the technical field of natural product extracts. A preparation method of the lobular broadleaf holly leaf extract comprises the following steps: taking high-quality and dry lobular broadleaf holly leaves, crushing, carrying out microwave treatment, and carrying out enzyme treatment; and carrying out water extraction and alcohol extraction, and separating the product. Compared with the prior art, the preparation method has the advantages that the dual advantages of microwave and enzyme treatment are ingeniously fused, the efficiency of the extract is greatly improved, the extract has a remarkable effect in the aspect of improving type 2 diabetes symptoms of model mice, the broadleaf holly leaf component is highly utilized, the loss of precious components is effectively reduced, and the preparation method is suitable for industrial production. The yield is obviously improved. Besides, the preparation method disclosed by the invention is comprehensively optimized in process, is simple and convenient to operate, is stable and reliable, and brings unprecedented development potential and broad prospects for the market.

The present application relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has an effect of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis, and lowering triglyceride levels.

The present invention relates to a composition effective in treating diabetes and dyslipidemia prepared according to the solid lipid nanotechnology from two natural phytochemical active ingredients: cinnamonaldehyde extracted from the Vietnamese cinnamon and berberine as a bioactive compound extracted from several plants, including a group of shrubs called Berberis. Via testing, all of the composition of the present invention has shown to have low toxicity and great bioavailability, reduced insulin resistance that allows the sugar level in blood to more effectively induce reduction of insulin, hyperglycolysis that aids the body in cellular sugar decomposition, reduced sugar production in the liver, carbohydrate decomposition slowed down in the intestines, and an increasing in the number of beneficial microbes in the intestines. The composition is effective in reducing the total cholesterol level (TC), and non-HDL-cholesterol, and has a tendency to reduce TG level.

The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal / cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.